# Steven Everett

> Steven Everett is a biotechnology executive and cancer scientist who founded MaveriX Oncology in Palo Alto, California, where he serves as President and CEO. With a background rooted in more than two decades of cancer research at the University of Oxford, University of Dundee and UCSF, he has built his career around a single idea: making cancer drugs that switch on only inside tumors. At MaveriX he is developing conditionally activated small-molecule therapeutics that exploit hydroxylase biology in the tumor immune microenvironment, aiming to hit cancer hard while sparing healthy tissue.

- **Role:** Founder, President & CEO at MaveriX Oncology, Inc.
- **Organizations:** MaveriX Oncology, Inc., Cyterix Pharmaceuticals, Threshold Pharmaceuticals, University of California San Francisco (UCSF), University of Dundee, University of Oxford, Cancer Research UK
- **Nationality:** British
- **Education:** BSc, Chemistry and Biology, University of Ulster, Ph.D., Radiation Chemistry and Biology, University of Ulster / Hahn-Meitner-Institut Berlin, MBA, University of London
- **Known for:** Founded MaveriX Oncology and developed the conditionally activated small-molecule drug conjugate (CA-SMDC) platform., Invented the OncoCYP-targeted prodrug discovery approach at Cyterix Pharmaceuticals., Author or co-author of more than 100 scientific publications.

## Career timeline

- **1992-2005** — Principal Investigator and Senior Scientist at the University of Oxford, Gray Institute, and Cancer Research UK.
- **2005-2009** — Head of the Drug Discovery and Translational Research Group at the University of Dundee, supported by Cancer Research UK.
- **2008-2010** — Entrepreneur-in-Residence and Scientific Advisor at Threshold Pharmaceuticals.
- **2010-2013** — Founding Director, President & CEO of Cyterix Pharmaceuticals; invented the OncoCYP-targeted prodrug discovery approach.
- **2014** — Founded MaveriX Oncology in Palo Alto, California.
- **2019** — MaveriX Oncology raised a Series A round; total funding reported around $7.5M.
- **2022** — MaveriX profiled in Nature for its conditionally activated small-molecule therapeutics co-targeting cancer and the tumor immune microenvironment.

## Achievements

- Founded MaveriX Oncology and developed the conditionally activated small-molecule drug conjugate (CA-SMDC) platform.
- Invented the OncoCYP-targeted prodrug discovery approach at Cyterix Pharmaceuticals.
- Author or co-author of more than 100 scientific publications.
- Named inventor on 50+ issued patents and patent applications.
- Secured 14 years of Cancer Research UK funding at project and program grant levels.
- Received the Steiner International Award for Cancer Research (2003).
- Led Series A and B financing rounds and international partnership deals across his companies.
- Professional member of the Royal Society of Chemistry and the Royal Society of Biology.

## Latest updates

- **2022-01** — MaveriX Oncology featured in Nature for its conditionally activated small-molecule therapeutics co-targeting cancer and the tumor immune microenvironment (TIME).
- **2024-03** — Updated leadership profile and photo published on the MaveriX Oncology website.

## Links

- Website: https://maverixoncology.com
- LinkedIn: http://www.linkedin.com/in/stevenaeverett
- Twitter/X: https://twitter.com/MaveriX_Onc_

---

Profile page: https://yespress.io/steven-everett
Published by YesPress — https://yespress.io
Last updated: 2026-07-24